<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336292">
  <stage>Registered</stage>
  <submitdate>30/11/2010</submitdate>
  <approvaldate>21/07/2011</approvaldate>
  <actrnumber>ACTRN12611000766910</actrnumber>
  <trial_identification>
    <studytitle>Clinical effects of N-acetylcysteine in the treatment of acute decompensated heart failure</studytitle>
    <scientifictitle>Randomised blinded control pilot trial investigating the effect of N-acetylcysteine in the treatment of acute decompensated heart failure</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute decompensated heart failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral N-acetylcysteine - 600mg twice daily for 5 days initiated within 24 hours of admission for acute decompensated heart failure</interventions>
    <comparator>Placebo-composed of the vehicle solution alone twice daily for 5 days initiated within 24 hours of admission for acute decompensated heart failure.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome will be the between group distribution of treatment success, treatment failure or no change in the patient?s clinical condition at Day 5.  Treatment success = improvement in symptoms at D5. Treatment failure = death, readmission, worsening symptoms or signs of HF at D5, worsening renal function (= &gt;27umol/L rise in creatinine).</outcome>
      <timepoint>Day 5 after hospital admission</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>The co-primary end-point is an improvement in forearm blood flow (measured by venous occlusion plethysmography and endoPAT).</outcome>
      <timepoint>Day 5 after hospital admission</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Death</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Worsening renal function (= &gt;27umol/L rise in creatinine)</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Re-hospitalization</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Worsening HF (KCCQ heart failure questionaire &amp; blinded clinical assessment by the treating physician)</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Hospital admission with acute decompensated HF including congestion (or) hypotension (or) worsening renal function (or) other end organ dysfunction.
-NYHA Class III or IV
-LVEF &lt; 40%</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age &lt; 18, and &gt;75
-LVAD or ECMO in situ or likely requirement for LVAD/ECMO within 24 hrs
-endotracheal intubation/ventilation
-cardiac or other solid organ transplantation
-STEMI at presentation
-Allergy to n-acetylcysteine
- pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All patients admitted to the Heart Failure service at the Alfred Hospital are screened for eligibility. Allocation is by sealed opaque envelopes generated randomly by clinical trials section in Alfred Hospital pharmacy.</concealment>
    <sequence>Random number generation by pharmacy</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/01/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Alfred Health</primarysponsorname>
    <primarysponsoraddress>Commercial Rd
Prahran VIC 3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Supported as a part of NHMRC Program Grant</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Heart failure is a condition cause by heart muscle weakness. As a result the circulation to the body becomes inefficient and blood flow tends to fall. We are studying whether a simple medicine which is used in other settings can improve blood flow and thus outcomes for patients admitted to hospital with heart failure.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Health Research and Ethics Committee</ethicname>
      <ethicaddress>Commercial Rd
Prahran
VIC 3181</ethicaddress>
      <ethicapprovaldate>26/11/2010</ethicapprovaldate>
      <hrec>1/10/0344</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof David Kaye</name>
      <address>Heart Centre
Alfred Hospital
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 9076 3263</phone>
      <fax />
      <email>d.kaye@alfred.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof David Kaye</name>
      <address>Heart Centre
Alfred Hospital
Commercial Rd
Prahran VIC 3181</address>
      <phone>+61 3 9076 3263</phone>
      <fax />
      <email>d.kaye@alfred.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>